IP Library Granted Patent US 9,228,204
Granted Patent B2
US 9,228,204 · App. 13/975,004 · Granted Jan 5, 2016

Constructs for making induced pluripotent stem cells

Inventors: Stefan M. Pulst (Salt Lake City, UT); Sharan Paul (Salt Lake City, UT); Warunee Dansithong (Salt Lake City, UT)
Assignee: University of Utah Research Foundation
C12N15/86C12N5/0696C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2510/00C12N2710/10343
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,228,204
App. No.
13/975,004
Granted
Jan 5, 2016
Kind
B2
Abstract

Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter.

Claims (13)

1. A transformation construct for generating induced pluripotent stem (iPS) cells, comprising:

an expression vector including a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter, wherein the plurality of reprogramming factors includes OCT3/4, SOX2, and at least one member selected from the group consisting of KLF4, c-Myc, NANOG, and LIN28.

2. The construct of claim 1 , wherein the expression vector is selected from the group consisting of plasmids, viruses, and combinations thereof.

3. The construct of claim 1 , wherein the expression vector is selected from the group consisting of adenoviral vectors, episomal vectors, retroviral vectors, and lentiviral vectors.

4. The construct of claim 1 , wherein the expression vector is an episomal vector.

5. The construct of claim 1 , wherein the plurality of reprogramming factors includes OCT3/4, SOX2, KLF4, and c-Myc.

6. The construct of claim 1 , wherein the plurality of reprogramming factors consists of OCT3/4, SOX2, and KLF4.

7. The construct of claim 1 , wherein the plurality of reprogramming factors includes OCT3/4, SOX2, NANOG, and LIN28.

8. The construct of claim 1 , wherein the expression vector has a sequence that is at least 80% homologous to SEQ ID 72.

9. The construct of claim 1 , wherein the expression vector has a sequence that is at least 95% homologous to SEQ ID 72.

10. The construct of claim 1 , wherein at least one of reprogramming factor is under the control of a CMV promoter.

11. The construct of claim 10 , wherein the CMV promoter is a weak CMV promoter.

12. The construct of claim 1 , wherein the expression vector further includes a reporter sequence under control of a separate promoter.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2015
From: PULST, STEFAN M.; PAUL, SHARAN; DANSITHONG, WARUNEE
To: UNIVERSITY OF UTAH
Reel/Frame 037093/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2015
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 037093/0875 →
CONFIRMATORY LICENSE Recorded May 18, 2015
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035706/0955 →
Continuity (4)
Continuation In Part 13960305 · Aug 6, 2013
Continuation PCTUS2012025117 · Feb 14, 2012
Provisional Application 61442695 · Feb 14, 2011
Related Publication 20140170752A1 · Jun 19, 2014